Results 11 to 20 of about 26,977 (247)

Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study

SAGE Open Medicine, 2016
Background: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.
Jane MacIver, Alana Tibbles, Filio Billia, Heather Ross   +3 more
doaj   +1 more source

Cardiac Magnetic Resonance Imaging–Derived Left Atrial Characteristics in Relation to Atrial Fibrillation Detection in Patients With an Implantable Cardioverter‐Defibrillator

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Among patients with an implantable cardioverter‐defibrillator, a high prevalence of atrial fibrillation (AF) is present. Identification of AF predictors in this patient group is of clinical importance to initiate appropriate preventive ...
Luuk H. G. A. Hopman, Anne‐Lotte C. J. van der Lingen, Nikki van Pouderoijen, Judith Krabbenborg, Mark J. Mulder, Mischa T. Rijnierse, Pranav Bhagirath, Lourens F. H. J. Robbers, Albert C. van Rossum, Vokko P. van Halm, Marco J. W. Götte, Cornelis P. Allaart   +11 more
doaj   +1 more source

Deactivation of implantable cardioverter-defibrillators [PDF]

Canadian Medical Association Journal, 2021
About 7000 implantable cardioverter-defibrillators are implanted annually in Canada to prevent sudden death.[1][1] However, patient preferences may change, and goals of care may shift to improving quality of life rather than preventing sudden demise. Shocks from implantable cardioverter-
Wan, Darryl, Chakrabarti, Santabhanu
openaire   +2 more sources

A Case of Silicone Allergy Induced by a Subcutaneous Implantable Cardioverter Defibrillator

Journal of Arrhythmia
Background Allergic reactions associated with subcutaneous implantable cardioverter‐defibrillator (S‐ICD) are extremely rare, and silicone‐related cases are scarcely reported.
Wataru Shinkai, Jun Kishihara, Megumi Toraiwa, Yuki Arakawa, Shuhei Kobayashi, Hironori Nakamura, Naruya Ishizue, Jun Oikawa, Hidehira Fukaya, Junya Ako   +9 more
doaj   +2 more sources

The implantable cardioverter‐defibrillator [PDF]

Clinical Cardiology, 2000
AbstractVentricular arrhythmias remain a major cause of cardiovascular mortality. Therapy for serious ventricular arrhythmias has evolved over the past decade, from treatment primarily with antiarrhythmic drugs to implanted devices. The implantable cardioverter‐defibrillator (ICD) is the best therapy for patients who have experienced an episode of ...
openaire   +2 more sources

Subcutaneous Implantable Cardioverter-Defibrillator [PDF]

Circulation, 2014
For nearly 3 decades, the implantable cardioverter-defibrillator (ICD) has been available to patients who survived life-threatening rapid heart rhythms or are at risk of experiencing them. The ICD comprises a device generator coupled with a defibrillation lead.
Philip M, Chang, Rahul, Doshi, Leslie A, Saxon   +2 more
openaire   +2 more sources

Implantable Cardioverter Defibrillator

Majalah Kardiologi Indonesia, 2013
Ide penggunaan Implantable Cardioverter Defibrillator (ICD) untuk pencegahan kematian jantung mendadak pertama kali dicetuskan oleh Dr. Michel Mirowski pada tahun 1970. Sejak itu ICD berkembang dari sebuah prototipe yang dicoba pada binatang menjadi alat
Dicky Armen Hanafy
doaj   +1 more source

Incidence and Costs Related to Lead Damage Occurring Within the First Year After a Cardiac Implantable Electronic Device Replacement Procedure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundInadvertent damage to leads for transvenous pacemakers, implantable cardioverter‐defibrillators, and cardiac resynchronization therapy defibrillators is an important complication associated with generator‐replacement procedures.
Christine I. Nichols, Joshua G. Vose, Suneet Mittal   +2 more
doaj   +1 more source

Use of Nonrecommended Drugs in Patients With Brugada Syndrome: A Danish Nationwide Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Patients with Brugada syndrome (BrS) are recommended to avoid drugs that may increase their risk of arrhythmic events. We examined treatment with such drugs in patients with BrS after their diagnosis.
Camilla H. B. Jespersen, Johanna Krøll, Priya Bhardwaj, Carl Johann Hansen, Jesper Svane, Bo G. Winkel, Christian Jøns, Peter Karl Jacobsen, Jens Haarbo, Jens Cosedis Nielsen, Jens Brock Johansen, Berit T. Philbert, Sam Riahi, Christian Torp‐Pedersen, Lars Køber, Jacob Tfelt‐Hansen, Peter E. Weeke   +16 more
doaj   +1 more source

New horizon for infection prevention technology and implantable device

Journal of Arrhythmia, 2016
There has been a significant increase in the number of patients receiving cardiovascular implantable electronic devices (CIED) over the last two decades.
Yusuke Kondo, MD, PhD, Marehiko Ueda, MD, PhD, Yoshio Kobayashi, MD, PhD, Joerg O. Schwab, MD, PhD   +3 more
doaj   +1 more source